Chemistry:Apolizumab
From HandWiki
Short description: Chemical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HLA-DR beta |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.[3]
References
- ↑ "Gateways to clinical trials". Methods and Findings in Experimental and Clinical Pharmacology 25 (9): 747–771. November 2003. PMID 14685303.
- ↑ "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study". Leukemia & Lymphoma 47 (10): 2147–2154. October 2006. doi:10.1080/10428190600757944. PMID 17071489.
- ↑ "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia". Leukemia & Lymphoma 50 (12): 1958–1963. December 2009. doi:10.3109/10428190903186486. PMID 19860603.
 |  |
